Erratum: Author correction to "Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers" [Acta Pharmaceutica Sinica B 11 (2021) 355-372]

Acta Pharm Sin B. 2022 Jun;12(6):2963-2964. doi: 10.1016/j.apsb.2022.02.028. Epub 2022 Mar 2.

Authors

Tingting Jiang¹, Guan Wang¹, Yao Liu¹, Lu Feng¹, Meng Wang¹, Jie Liu¹, Yi Chen², Liang Ouyang¹

Affiliations

¹ State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Chengdu 610041, China.
² State Key Laboratory of Biotherapy and Cancer Center and Department of Gastrointestinal Surgery, West China Hospital, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu 610041, China.

Abstract

[This corrects the article DOI: 10.1016/j.apsb.2020.05.004.].

© 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

Publication types

Published Erratum